Sunday, September 4, 2022

Just Some NASDAQ Trivia -- Over The Long Market-Shuttered Weekend... LQDA Edition / Shkreli


A kind commenter on another property reminded me that before Martin Shkreli's ability to access discord was ended, last week. . . Mr. Shkreli had been bragging that he had invested in a life science company (which company is now in a series of pitched patent battles), with the symbol LQDA, saying he was going to make stacks on it.

Not sure where he got the liquid funds to make any actual open brokerage account bet, but that is a story for another day. [Maybe he was, as is often the case. . . lying. Or perhaps the MSI.inu rug pull. Who knows? Who cares, really?]

In any event, the company is now over a year away for certain, from an FDA green-light under Hatch-Waxman, and it only won on one of the two patent battles it was waging.

Even so, from a high of over $11 a few weeks ago, to a low of about $4 early last week. . . it did rise on Friday, after some insiders bought small amounts of the company's shares (as the chart at right shows).

But -- whatever else may be said about this micro-cap, the horizon is well beyond where Martin ever trades. He usually is in and out in under three weeks -- often within days.

So it would not surprise me to learn that he bought some at around $4. . . and will dump it next week. . . at around $6 or $7.

Longer term, most big houses rate it an underweight / under-perform, due to the only potential drug product (called Yutrepia) now being over a year from FDA approval, at best -- even if it wins out on all the remaining patent appeals.

It also turns out that Watson Pharmaceuticals, a well-established generic, has the right by settlement agreement (see page 34 there), to enter on June 1, 2026 -- with its competing, and already green-lit generic alternative to Tyvaso (the branded), which will mean Yutrepia -- if approved, would only have about 11 months as the lone generic. . . then the floodgates open, and the prices will plummet, as Watson (the second generic) enters the US market.

So. . . it would be Condor's considered opinion, that Martin is riding along, in a pump and dump operation, perhaps even. . . along with management, of this intrepid company.

So it goes, and now you know. I had a hot cuppa', and some fresh dark Michigan cherries -- this quiet morning, and decided to take a bit of. . . a look.

Of course, do your own diligence.

नमस्ते

No comments: